NCT01280786

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Synta Pharmaceuticals Corp. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.

Detailed description

This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when administered to patients with advanced myeloid leukemia.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	Elesclomol Sodium	Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.

Timeline

• Start date: 2011-01-01
• Primary completion: 2014-06-01
• Completion: 2014-08-01
• First posted: 2011-01-21
• Last updated: 2014-02-03

Locations

1 site across 1 country: Canada